

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 08 2002

IN RE APPLICATION OF: Masako YAJIMA, et al.

SERIAL NO: 10/073,297

GAU: 1646

TECH CENTER 1600/2900

FILED: February 13, 2002

EXAMINER:

FOR: AGENTS FOR ALLEVIATING SYMPTOMS ACCOMPANIED BY INFLAMMATION

P#3

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).


CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


 Norman F. Oblon

Registration No. 24,618


 Tel. (703) 413-3000
 Fax. (703) 413-2220
 (OSMMN 10/98)

22850

 WILLIAM E. BEAUMONT
 REGISTRATION NUMBER 30,996

RECEIVED
MAY 07 2002
U.S. PATENT AND TRADEMARK OFFICE

MAY 08 2002

TECH CENTER 1600/2000 SHEET 1 OF 1

Form PTO 1449 (Modified)		DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 219451US0	SERIAL NO. 10/073,297		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT		Masako YAJIMA, et al.			
		FILING DATE February 13, 2002		GROUP 1646			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AE	0 584 558	03/02/94	EUROPE	YES	NO	
	AF						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AG	Patent Abstracts of Japan, JP 51-78759, July 20, 1993					
	AH	Patent Abstracts of Europe, EP 0 579 830, January 26, 1994					
	AI	Patent Abstracts of Japan, JP 7-300425, November 14, 1995					
	AJ	Patent Abstracts of Japan, JP 8-165248, June 25, 1996					
	AK	Patent Abstracts of Japan, JP 10-114675, May 6, 1998					
	AL	Patent Abstracts of Japan, JP 10-245347, September 14, 1998					
	AM	Patent Abstracts of Japan, JP 11-029600, February 2, 1999					
	AN	Patent Abstracts of Japan, JP 2000-229881, August 22, 2000					
	AO	E. ELASS-ROCHARD, et al., Infection and Immunity, vol. 66, no. 2, pages 486-491, "LACTOFERRIN INHIBITS THE ENDOTOXIN INTERACTION WITH CD14 BY COMPETITION WITH THE LIPOPOLYSACCHARIDE-BINDING PROTEIN", February 1998					
	AP	D. JEAN, et al., American Journal of Respiratory and Critical Care Medicine, vol. 158, pages 1702-1708, "PROTECTIVE EFFECT OF ENDOTOXIN INSTILLATION ON SUBSEQUENT BACTERIA-INDUCED ACUTE LUNG INJURY IN RATS", 1998					
	AQ	M. MACHNICKI, et al., Int. J. Exp. Path., vol. 74, pages 433-439, "LACTOFERRIN REGULATES THE RELEASE OF TUMOUR NECROSIS FACTOR ALPHA AND INTERLEUKIN 6 IN VIVO", 1993					
	AR	O. LEVY, Antimicrobial Agents and Chemotherapy, vol. 44, no.11, pages 2925-2931, " A NEUTROPHIL-DERIVED ANTI-INFECTIVE MOLECULE: BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN", November 2000					
Examiner					Date Considered		

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.